Idiopathic Pulmonary Fibrosis Cough Treatment Study
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, fibrotic interstitial lung disease of unknown cause, primarily occurring in older adults. The disease is characterised by chronic dry cough, dyspnoea on exertion, and loss of appetite and subsequent gradual weight loss.
This clinical study is designed to determine the efficacy of the study medication in chronic cough
associated with IPF.
Who can participate?
You may be eligible for this study if you:
- Have a current diagnosis of IPF established during the previous seven years
- Are not currently pregnant or breastfeeding
If you are eligible to be involved in the study, you will be asked to attend the clinic 7 times over a period of approximately 13 weeks. This includes a run-in period of up to 2 weeks followed by entering into the treatment phase of the study where you will receive active study medication. You will be asked to take the medication three times (3x) a day for approximately 12 weeks.
This study is currently looking for participants in NSW.
Click here to express your interest.